Plus Therapeutics Aims for REYOBIQ Pivotal Trial Readiness and CNSide Commercial Scale-Up in 2026
Event summary
- Plus Therapeutics completed a $15 million upsized offering to extend cash runway through 2027.
- REYOBIQ Phase 2 trial data for leptomeningeal metastases (ReSPECT-LM) expected in Q3 2026.
- CNSide commercial rollout targets 150 million US lives covered and 1,250 tests per year.
- ReSPECT-GBM Phase 2 trial for glioblastoma data expected in Q4 2026.
The big picture
Plus Therapeutics is focusing on scaling its CNSide diagnostics platform and advancing REYOBIQ through pivotal trials, aiming to address the critical unmet needs in central nervous system cancers. The company's strategic push aligns with the broader industry trend of developing targeted radiotherapeutics and precision diagnostics for rare and severe cancer complications. The $15 million funding round provides a financial buffer, but the success of its commercial and clinical milestones will determine its long-term viability in a competitive oncology market.
What we're watching
- Trial Execution
- Whether Plus Therapeutics can successfully complete pivotal trial designs for REYOBIQ in glioblastoma and pediatric brain cancer.
- Commercial Scale
- The pace at which CNSide achieves Medicare and Medicaid coverage and expands its testing platform.
- Funding Utilization
- How effectively the $15 million offering accelerates REYOBIQ commercial manufacturing and trial readiness.
Related topics